{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:59:07Z","timestamp":1792616347448,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.therap.2022.12.004","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T11:06:09Z","timestamp":1670583969000},"page":"754-756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Secukinumab-induced vitiligo: A new case report and review of the literature"],"prefix":"10.1016","volume":"78","author":[{"given":"Sana","family":"Bouzid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houda","family":"Hammami-Ghorbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Chamli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imen","family":"Aounti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiem","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Kochbati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Fenniche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anissa","family":"Zaouak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2022.12.004_bib0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000087013","article-title":"Cutaneous adverse events of biological therapy for psoriasis: review of the literature","volume":"211","author":"Thielen","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.therap.2022.12.004_bib0060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaci.2015.10.023","article-title":"Alterations in immune function with biologic therapies for autoimmune disease","volume":"137","author":"Her","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.therap.2022.12.004_bib0065","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.therap.2022.03.001","article-title":"Pharmacovigilance and drug safety: fair prescribing and clinical research","volume":"77","author":"Montastruc","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.12.004_bib0070","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2230.2010.03972.x","article-title":"Role of interleukin-17 in the pathogenesis of vitiligo: role of IL-17 in the pathogenesis of vitiligo","volume":"36","author":"Bassiouny","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.therap.2022.12.004_bib0075","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.autrev.2016.01.004","article-title":"The role of IL-17 in vitiligo: a review","volume":"15","author":"Singh","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.therap.2022.12.004_bib0080","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.3389\/fimmu.2019.01918","article-title":"Learning from success and failure: biologics for non-approved skin diseases","volume":"10","author":"Speeckaert","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.therap.2022.12.004_bib0085","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/jdv.13759","article-title":"New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases","volume":"31","author":"M\u00e9ry-Bossard","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.therap.2022.12.004_bib0090","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s40261-020-00964-w","article-title":"New-onset vitiligo during treatment with secukinumab: report of two cases and review of the literature","volume":"40","author":"Nieto-Benito","year":"2020","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.therap.2022.12.004_bib0095","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000510831","article-title":"Vitiligo with progressive repigmentation during secukinumab treatment in a patient with psoriatic arthritis: a case report","volume":"13","author":"Giordano","year":"2021","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.therap.2022.12.004_bib0100","doi-asserted-by":"crossref","first-page":"omz134","DOI":"10.1093\/omcr\/omz134","article-title":"Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris","volume":"2020","author":"Palazzo","year":"2020","journal-title":"Oxf Med Case Reports"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595722002785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595722002785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:55:45Z","timestamp":1758567345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595722002785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0040595722002785"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2022.12.004","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secukinumab-induced vitiligo: A new case report and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2022.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}